Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multi-epitopes.CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging...
April 26, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market

Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.OSE Immunotherapeutics to receive up to €315 million in potential...
April 06, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach...
April 01, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses.CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and...
March 26, 2021 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update

Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2...
March 15, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,...
March 11, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting

CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 to...
February 23, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
February 17, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011

NANTES, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its...
February 15, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,Divided into three tranches including...